Related Experiment Video

Updated: Dec 17, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.2K

Recent Patents on the Development of c-Met Kinase Inhibitors

Xiangming Xu1, Lei Yao2

  • 1Department of Gastroenterology, Linyi People's Hospital, No. 27, Eastern Jiefang Road, Lanshan District, Linyi 276000, Shandong, China.

Recent Patents on Anti-Cancer Drug Discovery
|July 1, 2020
PubMed
Abstract

Insights

Recent patents reveal promising c-Met kinase inhibitors, derived from natural products and synthetic origins, for cancer treatment. These inhibitors show potent antitumor activity, particularly for Non-Small Cell Lung Cancer (NSCLC) with resistance.

Area of Science:

  • Oncology
  • Drug Discovery
  • Molecular Biology

Background:

  • Receptor Tyrosine Kinases (RTKs) are crucial in cell growth, differentiation, angiogenesis, and cancer development.
  • The c-Met kinase, a type of RTK, is a significant target for anti-tumor drug development.
  • c-Met inhibitors offer potential in cancer prevention, chemotherapy, biotherapy, and overcoming tumor resistance.

Purpose of the Study:

  • To review recent advancements in c-Met inhibitors.
  • Focus on inhibitors reported in patents since 2015.

Main Methods:

  • Comprehensive literature review using Scifinder and Web of Science.
  • Identification of c-Met inhibitors published in patents from 2015 onwards.

Main Results:

  • Identified two classes of c-Met inhibitors: natural products and synthetic compounds.
  • Most inhibitors demonstrated potent in vitro and in vivo antitumor activities.
  • These inhibitors show therapeutic potential for various cancers.

Conclusions:

  • c-Met kinase inhibitors represent a novel drug class for diverse cancers.
  • Particularly promising for Non-Small Cell Lung Cancer (NSCLC) with acquired resistance.
  • Further research into natural product-derived c-Met inhibitors is warranted.
Keywords:
Cancerc-Metinhibitorspatentprogressreceptor tyrosine kinases

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.4K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K